Patent intelligence · CA
CA 2512780
PRODUITS DE SYNTHESE MULTIVALENTS POUR APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES
PRODUITS DE SYNTHESE MULTIVALENTS POUR APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES
Patent details — CA 2512780
- Jurisdiction
- CA
- Status
- expired
- Grant date
- Aug 5, 2004
- Expiration
- Jul 31, 2024
- Applicant
- BRACCO INT BV [NL]
- CPC classes
- A61K 38/ 00 A I, A61K 47/ 48 A I, A61K 49/ 00 A I, A61K/4760
Quick answer
CA 2512780 (PRODUITS DE SYNTHESE MULTIVALENTS POUR APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES) is held by BRACCO INT BV [NL]. Status: expired. Granted Aug 5, 2004. Expires Jul 31, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRACCO INT BV [NL]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 00 A I, A61K 47/ 48 A I, A61K 49/ 00 A I, A61K/4760, A61K/4764, A61K38/00
More from BRACCO INT BV [NL]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 2512780?
CA 2512780 (PRODUITS DE SYNTHESE MULTIVALENTS POUR APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES) is held by BRACCO INT BV [NL]. Status: expired. Granted Aug 5, 2004. Expires Jul 31, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2512780?
BRACCO INT BV [NL] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2512780 expire?
Our index shows an expiration date of Jul 31, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.